Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function

NCT ID: NCT02467790

Last Updated: 2016-01-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-02-28
• Study Completion Date: 2016-05-31

Brief Summary

To compare and analysis pharmacokinetics of PEX 168 in patients with renal insufficiency or normal renal function who were administrated subcutaneously single dose PEX168.To evaluate dose adjustment of PEX168 administered in patients with renal insufficiency and provide a scientific basis in patients with renal insufficiency of rational drug use.

Detailed Description

This is an open, non-randomized, parallel-group, single-dose study that evaluated the pharmacokinetics of PEX168 when single dose administered with PEX168 in patients with renal insufficiency and normal renal function subjects. The total duration of each subject's participation in the study was approximately 45 days, which included up to a 14-day Screening Period, a 31-day PK sample collecting Period.

Center: This study was conducted at two sites in the Third Xiangya hospital of Center South University and Shanghai Changhai Hospital.All subjects receives a single 200μg doses of PEX168 injected subcutaneously on Day 1.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Mild renal insufficiency

PEX 168: 200µg,Subcutaneous,one time.

Group Type: EXPERIMENTAL

PEX168

Intervention Type: DRUG

PEX 168: 200µg,Subcutaneous,one time.

Moderate renal insufficiency

PEX 168: 200µg,Subcutaneous,one time.

Group Type: EXPERIMENTAL

PEX168

Intervention Type: DRUG

PEX 168: 200µg,Subcutaneous,one time.

Normal renal function

PEX 168: 200µg,Subcutaneous,one time.

Group Type: EXPERIMENTAL

PEX168

Intervention Type: DRUG

PEX 168: 200µg,Subcutaneous,one time.

Interventions

PEX168

PEX 168: 200µg,Subcutaneous,one time.

Intervention Type: DRUG

Other Intervention Names

Polyethylene Glycol Loxenatide

Eligibility Criteria

Inclusion Criteria

1. Age 31-65 (both inclusive) years old, male or female;

2. Weight: Male ≥50kg, female ≥45kg, 18≤BMI≤28;

3. The Cockcroft-Gault (CG) formula to estimate creatinine clearance (CLCr), K / DOQI definition of chronic kidney disease (CKD) 2 patients: 60≤CLcr≤89 ml / min; chronic kidney disease (CKD) 3 patients: 30≤CLcr≤59 ml / min for renal insufficiency,Cockcroft-Gault (CG) formula to estimate creatinine clearance (CLCr) ≥90ml / min for normal subjects.

4. In the 48 hours before the start of the test to the end of the trial period, agreed to get rid of tobacco, alcohol, caffeine, fruit juice subject;

5. Understand the study procedures and methods, voluntarily participate in this experiment, and writing and signed informed consent.

Exclusion Criteria

1. Known or suspected of GLP-1 class of drug allergy or allergy;

2. Before screening,received GLP-1 receptor agonists, GLP-1 analogs, DPP-IV inhibitors or any other similar structure of the drug treatment;

3. In addition to the induced renal dysfunction disease itself, suffering from any other organ of acute illness and those with any influence of drugs in vivo study of chronic diseases;

4. within 6 months prior to screening,having any surgery, including the impact of gastric emptying of gastrointestinal surgery;

5. Screened within the previous three months to participate in blood donation and blood donation ≥400mL, or who participate in blood donation or blood transfusion within one month;

6. Within 3 months before screening participated in any drug or medical device trials are (including placebo);

7. Drinking, smoking addiction, drug abuse and drug abusers;

8. In addition to judging laboratory abnormalities diagnosis of renal dysfunction caused by disease, there are other clinically significant laboratory abnormalities (Note: Patients with moderate to severe anemia (Hb <60g / L), severe hypertension ( SBP> 160mmHg and / or diastolic blood pressure> 100mmHg) patients, heart rate> 100bmp, ECG QTc> 450ms were required to exclude;

9. ALT> 1.5 times the upper limit of normal and / or aspartate transaminase> 1.5 times the upper limit of normal and / or total bilirubin> 1.5 times the upper limit of normal;

10. Fasting triglycerides> 5.64mmol / L (500mg / dl);

11. Beyond the normal range of serum amylase, and the clinical significance is determined by the investigator;

12. Pancreatitis, pancreatic cancer a history;

13. Blood thyroid stimulating hormone (TSH) beyond the normal range and clinically significant judgment by the investigator;

14. The pregnancy test was positive women of childbearing age, or pregnant women, breastfeeding women, and within six months there have been unwilling or unable to take family planning and effective contraception during the trial of male / female volunteers;

15. The hepatitis B surface antigen, hepatitis C antibody, HIV antibody, syphilis antibody test positive;

16. Researchers believe any situation that might lead to any subject can not be completed or to the subject of this study bring significant risk.

• Minimum Eligible Age: 31 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Guoping Yang, MD

Role: PRINCIPAL_INVESTIGATOR

The Third Xiangya Hospital,Center South University

Locations

Third Xiangya Hospital, Central South Univety

Changsha, Hunan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Hao Zhang, MD

Role: CONTACT

zhanghaoliaoqin@163.com

13975806919

Guoping Yang, MD

Role: CONTACT

ygp9880@163.com

13974817168

Facility Contacts

Hao Zhang, MD

Role: primary

zhanghaoliaoqin@163.com

13975806919

Guoping Yang, MD

Role: backup

ygp9880@163.com

13974817168

References

Wang J, Huang J, Li W, Tang S, Sun J, Zhang X, Liu J, Yi B, Liu J, Zhang X, Yang Q, Yang X, Yang S, Yang G, Zhang H. Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. Br J Clin Pharmacol. 2019 Dec;85(12):2714-2720. doi: 10.1111/bcp.14091. Epub 2019 Dec 8.

Reference Type: DERIVED

PMID: 31396983 (View on PubMed)

Other Identifiers

PEX168-Ih

Identifier Type: -

Identifier Source: org_study_id